Clinical Trials Logo

Clinical Trial Summary

The primary purpose of this study is to evaluate the safety and preliminary efficacy of microplasmin when administered intravenously to patients who have suffered an acute stroke within 12 hours before randomization.


Clinical Trial Description

While the primary objective of the trial is safety evaluation, efficacy assessments will also be obtained, including MRI/MRA (including DWI, PWI and T2 imaging) and plasma surrogate biomarkers. Clinical outcome will also be assessed at 7days, 30 days and 90 days post-treatment. At each of these visits, mortality and neurological assessments (NIHSS, Barthel index, mRankin scale) will be performed. In addition, vital status will be assessed vial a telephone contact at 60 days post-treatment.

The trial will investigate three dose regimens of microplasmin, all of which are within the range of doses previously evaluated in a Phase I trial in healthy volunteers; the planned sample size for the trial is approximately 40 patients.

The study will consist of 3 phases - the Baseline, In-hospital Phase and Follow up Phase. Baseline is from study entry through randomisation; the In-hospital phase is from treatment with study drug through hospital discharge or day 7, whichever occurs first. The follow up phase consists of visits to the hospital 30 days (+ 3 days) from the day of study drug administration. Hospital discharge is defined as the end of the discharge from the acute hospital setting. Discharge may be to home, to a rehabilitation setting or to a non-acute hospital setting. ;


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00123305
Study type Interventional
Source ThromboGenics
Contact
Status Completed
Phase Phase 2
Start date October 2005
Completion date June 2008

See also
  Status Clinical Trial Phase
Recruiting NCT03132558 - Contrast Induced Acute Kidney in Patients With Acute Stroke N/A
Recruiting NCT02541578 - Physiological Complexity of Gait Over the First Six Months Post Stroke N/A
Recruiting NCT02893631 - Assessment of Hemostasis Disorders in rtPA-treated Patients Requiring Endovascular Treatment for Ischemic Stroke N/A
Active, not recruiting NCT02274727 - Biomarker Signature of Stroke Aetiology Study: The BIOSIGNAL-Study
Recruiting NCT02225730 - Imaging Collaterals in Acute Stroke (iCAS) N/A
Terminated NCT01705353 - The Role of HMGB-1 in Chronic Stroke N/A
Active, not recruiting NCT01581502 - SAMURAI-NVAF Study: Anticoagulant Therapy for Japanese Stroke Patients With Nonvalvular Atrial Fibrillation (NVAF) N/A
Completed NCT01182818 - Fabry and Stroke Epidemiological Protocol (FASEP): Risk Factors In Ischemic Stroke Patients With Fabry Disease N/A
Completed NCT00761982 - Autologous Bone Marrow Stem Cells in Middle Cerebral Artery Acute Stroke Treatment. Phase 1/Phase 2
Completed NCT00535197 - Autologous Bone Marrow Stem Cells in Ischemic Stroke. Phase 1/Phase 2
Terminated NCT00132509 - FRALYSE Trial: Comparison of the Classical Rt-PA Procedure With a Longer Procedure in Acute Ischemic Stroke Phase 2
Recruiting NCT03235271 - Pilot Study of Acute Stroke Using the Brainpulseâ„¢
Recruiting NCT03324321 - Feasibility of Improving Cerebral Autoregulation in Acute Intracerebral Haemorrhage N/A
Recruiting NCT02989376 - Carotid Duplex Ultrasound for Selecting Patients for Endovascular Thrombectomy in Acute Stroke Patients N/A
Recruiting NCT02207023 - Healthy Lifestyles After Stroke N/A
Completed NCT01957774 - THR-18's Pharmacokinetics and Pharmacodynamics in Subjects With Acute Ischemic Stroke Treated With tPA Phase 2
Recruiting NCT02002390 - Efficacy and Safety of FTY720 for Acute Stroke Phase 2
Active, not recruiting NCT01327989 - Solitaire FR Thrombectomy for Acute Revascularisation N/A
Recruiting NCT03296852 - Study: SONAS Ultrasound for Detecting Stroke SONAS Ultrasound for Detecting Stroke Early Phase 1
Recruiting NCT03245957 - HDL Dysfunction During the Acute Stage of Stroke N/A